Reger Michael K, Zollinger Terrell W, Liu Ziyue, Jones Josette, Zhang Jianjun
Department of Epidemiology, Indiana University Richard M. Fairbanks School of Public Health, 714 N Senate Avenue, Suite EF250F, Indianapolis, IN, 46202, USA.
College of Health Professions, Ferris State University, Big Rapids, MI, USA.
Eur J Nutr. 2016 Apr;55(3):1029-40. doi: 10.1007/s00394-015-0917-y. Epub 2015 May 6.
Experimental studies suggest that phytoestrogen intake alters cancer and cardiovascular risk. This study investigated the associations of urinary phytoestrogens with total cancer (n = 79), cardiovascular (n = 108), and all-cause (n = 290) mortality among 5179 participants in the continuous National Health and Nutrition Examination Survey (1999-2004).
Urinary phytoestrogens were measured using high-performance liquid chromatography with tandem mass spectrometric detection. Survival analysis was performed to evaluate hazard ratios (HRs) and 95 % confidence intervals (CIs) for each of the three outcomes in relation to urinary phytoestrogens.
After adjustment for confounders, higher urinary concentrations of total enterolignans were associated with a reduced risk of death from cardiovascular disease (HR for tertile 3 vs. tertile 1 0.48; 95 % CI 0.24, 0.97), whereas higher urinary concentrations of total isoflavones (HR for tertile 3 vs. tertile 1 2.14; 95 % CI 1.03, 4.47) and daidzein (HR for tertile 3 vs. tertile 1 2.05; 95 % CI 1.02, 4.11) were associated with an increased risk. A reduction in all-cause mortality was observed for elevated urinary concentrations of total enterolignans (HR for tertile 3 vs. tertile 1 0.65; 95 % CI 0.43, 0.96) and enterolactone (HR for tertile 3 vs. tertile 1 0.65; 95 % CI 0.44, 0.97).
Some urinary phytoestrogens were associated with cardiovascular and all-cause mortality in a representative sample of the US population. This is one of the first studies that used urinary phytoestrogens as biomarkers of their dietary intake to evaluate the effect of these bioactive compounds on the risk of death from cancer and cardiovascular disease.
实验研究表明,摄入植物雌激素会改变癌症和心血管疾病风险。本研究在连续进行的美国国家健康与营养检查调查(1999 - 2004年)的5179名参与者中,调查了尿植物雌激素与总癌症(n = 79)、心血管疾病(n = 108)及全因(n = 290)死亡率之间的关联。
采用高效液相色谱 - 串联质谱检测法测定尿植物雌激素。进行生存分析以评估与尿植物雌激素相关的三种结局各自的风险比(HRs)和95%置信区间(CIs)。
在对混杂因素进行调整后,尿中总肠内酯浓度较高与心血管疾病死亡风险降低相关(三分位数3与三分位数1相比,HR为0.48;95% CI为0.24, 0.97),而尿中总异黄酮(三分位数3与三分位数1相比,HR为2.14;95% CI为1.03, 4.47)和大豆苷元(三分位数3与三分位数1相比,HR为2.05;95% CI为1.02, 4.11)浓度较高与风险增加相关。尿中总肠内酯(三分位数3与三分位数1相比,HR为0.65;95% CI为0.43, 0.96)和肠内酯(三分位数3与三分位数1相比,HR为0.65;95% CI为0.44, 0.97)浓度升高可观察到全因死亡率降低。
在美国人群的代表性样本中,某些尿植物雌激素与心血管疾病和全因死亡率相关。这是首批将尿植物雌激素用作其膳食摄入量生物标志物来评估这些生物活性化合物对癌症和心血管疾病死亡风险影响的研究之一。